Novo Nordisk must stay ready to increase Wegovy sales, says CFO
Serious production difficulties in the US mean that Novo Nordisk wil only receive limited amounts of obesity drug Wegovy over the next six months. However, the company promises that its salespeople are chomping at the bit to get going as soon as the problems are solved.
by marketwire, translated by catherine brett
Novo Nordisk's latest issue with meeting patient demand for obesity drug Wegovy arose just one week after its sales force were called to a meeting in Las Vegas to prepare a large-scale sales campaign.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
US manufacturer cannot supply Wegovy injector pen syringes
For subscribers
.jpg&w=384&q=75)
